Cerity Partners LLC Has $1.31 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Cerity Partners LLC grew its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 19.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,897 shares of the medical equipment provider’s stock after buying an additional 1,966 shares during the period. Cerity Partners LLC’s holdings in Lantheus were worth $1,306,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Moloney Securities Asset Management LLC acquired a new stake in shares of Lantheus in the third quarter valued at about $1,066,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Lantheus in the second quarter valued at about $290,000. Massachusetts Financial Services Co. MA acquired a new stake in shares of Lantheus in the third quarter valued at about $25,955,000. Van ECK Associates Corp increased its stake in shares of Lantheus by 58.6% in the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider’s stock valued at $6,469,000 after buying an additional 21,604 shares during the period. Finally, Swedbank AB grew its stake in Lantheus by 21.1% during the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after purchasing an additional 125,843 shares during the period. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of Lantheus stock opened at $88.51 on Wednesday. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The stock has a 50 day moving average price of $100.44 and a two-hundred day moving average price of $97.49. The stock has a market capitalization of $6.15 billion, a PE ratio of 14.73 and a beta of 0.45.

Analysts Set New Price Targets

LNTH has been the subject of several recent analyst reports. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities decreased their target price on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research note on Thursday, November 7th. Truist Financial reaffirmed a “buy” rating and set a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, Redburn Atlantic initiated coverage on Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price for the company. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $125.71.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.